Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06531447

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Elchin Mansurov

Baku, AZ1011, Azerbaijan

About this study

Using combination of gemcitabine plus cisplatine as first line treatment patients with locally advanced breast cancer with high TUBB3 expression

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

IIIC stage breast cancer patients

Exclusion criteria

Other stages breast cancer patients

Treatment and study plan

Cisplatin

Drug

Every 21 days 6 cycles

Other names: CDDP

Gemcitabine

Drug

Every 21 days (First and 8th days) 6 cycles

Other names: Gemcitabine hydrochlorid

Doxorubicin

Drug

Every 21 days 4 cycles

Cyclophosphamide

Drug

Every 21 days 4 cycles

paclitaxel

Drug

Every 21 days 4 cycles or once a week for 12 weeks

Primary outcomes

  1. Clinical tumor regression rate

    Time frame: 4 months

    Chemotherapy combination Gemcitabine with Cisplatin

Secondary outcomes

  1. Increasing PFS and OS

    Time frame: 5 years and 10 years

    Observation after chemotherapy

Sponsors and collaborators

Lead sponsor

The National Center of Oncology, Azerbaijan

Other Gov

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2027
First posted
Aug 1, 2024
Registry last updated
Aug 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.